Acadia Pharmaceuticals | ACAD - Current Liabilities


Acadia Pharmaceuticals reported $356.58M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Eisai JPY 378.25B 33.36B Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Moderna USD 1.68B 109M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prothena USD 51.44M 16.37M Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025